# US 2023/0265199 A1 · Compositions and methods for treating and preventing inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265199 A1
- Document ID: US20230265199A1
- Status: Published application
- Kind: A1
- Application number: 18/188,707
- Filed: 2023-03-23
- Published: 2023-08-24
- Earliest claimed: 2014-09-05
- Assignees: Rsem, Limited Partnership
- Applicants: Rsem, Limited Partnership
- Inventors: Przemyslaw Sapieha; Normand Beaulieu
- Web page: https://patentgrep.com/patent/US20230265199A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/22: against growth factors {; against growth regulators}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling.

## Claims

### Claim 1

A method of treating or preventing inflammation comprising inhibiting NRP1-dependent cell-signaling in a subject.

### Claim 2

A method of preventing or reducing hyperactivation of innate immune response comprising inhibiting NRP1-dependent cell-signaling in a subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein said hyperactivation of innate immune response comprises i) secretion of IL-6, IL-1β and TNFα and/or recruitment of mononuclear phagocytes (MPs).

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein inhibiting NRP1-dependent cell-signaling comprises:
(a) reducing NRP1 expression or activity; and/or
(b) reducing NRP1 ligand expression or activity;
wherein said NRP1 ligand is SEMA3A, VEGF and/or TGF-β.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method comprises (i) reducing NRP1 activity by inhibiting the binding of NRP1 to at least one NRP1 ligand.

### Claim 6 (depends on 5)

The method of claim 5, wherein the NRP1 ligand is SEMA3A, VEGF or TGF-β.

### Claim 7 (depends on 5, 6)

The method of claim 5 or 6, wherein inhibiting the binding of NRP1 to at least one NRP1 ligand comprises administering an anti-NRP1 antibody or an NRP1 trap, wherein said trap comprises a NRP1 polypeptide or a functional fragment or variant thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein said NRP1 polypeptide corresponds to soluble NRP1 isoform 2.

### Claim 9 (depends on 8)

The method of claim 8, wherein said soluble NPR1 isoform 2 comprises or consists essentially of a polypeptide having an amino acid sequence as set forth in FIG. 22 without a signal peptide.

### Claim 10 (depends on 7)

The method of claim 7, wherein said NRP1 polypeptide corresponds to the extracellular domain of an NRP1 isoform 1 polypeptide.

### Claim 11 (depends on 10)

The method of claim 10, wherein said NRP1 isoform 1 polypeptide is as set forth in FIG. 26 and wherein said extracellular domain comprises amino acids 22 to 859 of the NRP1 polypeptide shown in FIG. 26 (residues 22 to 859 of SEQ ID NO: 66).

### Claim 12 (depends on 7, 8, 9, 10, 11)

The method of any one of claims 7 to 11, wherein said NRP1 trap comprises an NRP1 polypeptide comprising (i) amino acids 22 to 609 of a NRP1 polypeptide as set forth in SEQ ID NO: 65; (ii) amino acids 22 to 859 of a NRP1 polypeptide as set forth in SEQ ID NO: 66; (iii) amino acids 22 to 859 of a NRP1 polypeptide as set forth in SEQ ID NO: 69 (iv) or a functional fragment or functional variant of (i), (ii) or (iii).

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

The method of any one of claims 7 to 12, wherein said anti-NRP1 antibody inhibits the binding of SEMA3A to NPR-1 but does not substantially inhibit the binding of VEGF to NRP1 and wherein said NRP1 trap binds to SEMA3A but does not substantially bind to VEGF165 or has a reduced binding affinity for VEGF165 compared to SEMA3A binding affinity.

### Claim 14 (depends on 13)

The method of claim 13, wherein said NRP1 trap (i) lacks completely or partially domain b1 and/or b2 of NRP1; or (ii) comprises at least one amino acid point mutation which inhibits VEGF binding to NRP1.

### Claim 15 (depends on 13)

The method of claim 13, wherein said anti-NRP1 antibody does not bind to domain b1 and/or b2 of NRP1.

### Claim 16 (depends on 14)

The method of claim 14, wherein said point mutation comprises (a) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to tyrosine 297 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26; (b) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to aspartic acid 320 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26; and/or (c) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to glutamic acid 319 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26.

### Claim 17 (depends on 16)

The method of claim 16, wherein said point mutation is a Y297A substitution; a D320K substitution and/oror a E319K substitution.

### Claim 18 (depends on 7, 8, 9, 10, 11, 12)

The method of any one of claims 7 to 12, wherein said NRP1 trap:
(a) comprises domains a1, a2, b1, b2, and c and of said NRP1 polypeptide;
(b) comprises domains a1, a2, b1 and b2 of said NRP1 polypeptide;
(c) comprises domains a1, a2, and b1 of said NRP1 polypeptide;
(d) comprises domains a1 and a2 said NRP1 polypeptide;
(e) comprises domain b1 of said NRP1 polypeptide, wherein said domain b1 comprises at least one point mutation at an amino acid residue corresponding to (i) tyrosine 297; (ii) aspartic acid 320 and/or (iii) glutamic acid 319, of a NRP1 polypeptide comprising an amino acid sequence as set forth in FIG. 26, wherein said at least one mutation reduces or abrogates binding to VEGF165;
(f) lacks completely or partially domain c of said NRP1 polypeptide;
(g) lacks completely or partially domain b1 of said NRP1 polypeptide;
(h) lacks completely or partially domain b2 of said NRP1 polypeptide;
(i) lacks domains b1 and b2 of said NRP1 polypeptide; or
(j) lacks domains b1, b2 and c of said NRP1 polypeptide.

### Claim 19 (depends on 18)

The method of claim 18, wherein (i) said domain a1 comprises or consists essentially of an amino acids sequence corresponding to amino acids 27 to 141 of an NRP1 polypeptide as set forth in FIG. 26; (ii) said domain a2 comprises an amino acid sequence corresponding to amino acids 147 to 265 of an NRP1 polypeptide as set forth in FIG. 26; (iii) said domain b1 comprises an amino acids sequence corresponding to amino acids 275 to 424 of an NRP1 polypeptide as set forth in FIG. 26; (iv) said domain b2 comprises an amino acids sequence corresponding to amino acids 431 to 583 of an NRP1 polypeptide as set forth in FIG. 26; and/or (v) said domain c domain comprises an amino acids sequence corresponding to amino acids 645 to 811 of an NRP1 polypeptide as set forth in FIG. 26.

### Claim 20 (depends on 18)

The method of claim 18, wherein (i) said domain a1 comprises or consists essentially of an amino acids sequence corresponding to amino acids 22 to 148 of an NRP1 polypeptide as set forth in FIG. 26; (ii) said domain a2 comprises an amino acid sequence corresponding to amino acids 149 to 275 of an NRP1 polypeptide as set forth in FIG. 26; (iii) said domain b1 comprises an amino acids sequence corresponding to amino acids 276 to 428 of an NRP1 polypeptide as set forth in FIG. 26; (iv) said domain b2 comprises an amino acids sequence corresponding to amino acids 429 to 589 of an NRP1 polypeptide as set forth in FIG. 26; and/or (v) said domain c domain comprises an amino acids sequence corresponding to amino acids 590 to 859 of an NRP1 polypeptide as set forth in FIG. 26.

### Claim 21 (depends on 7)

The method of claim 7, wherein said method comprises inhibiting the binding of NRP1 to at least one NRP1 ligand by administering a NRP1 trap consisting essentially of a trap as set forth in Table 1 or a functional variant thereof.

### Claim 22 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 7 to 20, wherein said NRP1 trap further comprises a protein purification domain.

### Claim 23

The method of 22, wherein said purification domain is a polyhistidine tag.

### Claim 24 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 7 to 20, wherein said NRP1 trap further comprises a FC domain.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22 to 24, wherein said NRP1 trap comprises a protease or peptidase cleavage site enabling said protein purification domain or FC domain to be removed from said NRP1 trap.

### Claim 26 (depends on 25)

The method of claim 25, wherein said protease or peptidase is a TEV protease cleavage site.

### Claim 27 (depends on 26)

The method of claim 26, wherein said TEV protease cleavage site comprises the amino acid sequence GSKENLYFQG.

### Claim 28 (depends on 4)

The method of claim 4, wherein the method comprises reducing NRP1 ligand expression or activity, and wherein the NRP1 ligand is SEMA3A.

### Claim 29 (depends on 28)

The method of claim 28, comprising reducing SEMA3A activity by inhibiting SEMA3A binding to NRP1 by administering an anti-SEMA3A antibody which binds to the SEMA domain of SEMA3A.

### Claim 30

The method of 4, wherein said method comprises reducing NRP1 expression by administering a NRP1 antisense, shRNA or siRNA.

### Claim 31

The method of 4, wherein said method comprises reducing SEMA3A expression by administering a SEMA3A antisense, shRNA or siRNA.

### Claim 32

A NRP1 polypeptide trap comprising a NRP1 polypeptide or a functional fragment or variant thereof which binds to SEMA3A, VEGF165 and/or TGF-β.

### Claim 33 (depends on 32)

The NRP1 polypeptide trap of claim 32, wherein said NRP1 polypeptide corresponds to soluble NRP1 isoform 2.

### Claim 34 (depends on 33)

The NRP1 polypeptide trap of claim 33, wherein said soluble NPR1 isoform 2 comprises or consists essentially of a polypeptide having an amino acid sequence as set forth in FIG. 22 without a signal peptide.

### Claim 35 (depends on 34)

The NRP1 polypeptide trap of claim 34, wherein said NRP1 polypeptide corresponds to the extracellular domain of an NRP1 isoform 1 polypeptide.

### Claim 36 (depends on 35)

The NRP1 polypeptide trap of claim 35, wherein said NRP1 isoform 1 polypeptide is as set forth in FIG. 26 and wherein said extracellular domain corresponds to amino acids 22 to 859 of the NPR1 polypeptide shown in FIG. 26 (residues 22 to 859 of SEQ ID NO: 66).

### Claim 37 (depends on 32, 33, 34, 35, 36)

The NRP1 polypeptide trap of any one of claims 32 to 36, wherein said NRP1 trap comprises an NRP1 polypeptide comprising (i) amino acids 22 to 609 of a NRP1 polypeptide as set forth in SEQ ID NO: 65; (ii) amino acids 22 to 859 of a NRP1 polypeptide as set forth in SEQ ID NO: 66; (iii) amino acids 22 to 859 of a NRP1 polypeptide as set forth in SEQ ID NO: 69 (iv) or a functional fragment or functional variant of (i), (ii) or (iii).

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The NRP1 polypeptide trap of claim any one of claims 32 to 37, wherein NRP1 trap binds to SEMA3A but does not substantially bind to VEGF165 or has a reduced binding affinity for VEGF165 as compared to SEMA3A binding affinity.

### Claim 39 (depends on 38)

The NRP1 polypeptide trap of claim 38, wherein said NRP1 trap (i) lacks completely or partially domain b1 and/or b2 of NRP1; or (ii) comprises at least one amino acid point mutation which inhibits VEGF binding to NRP1.

### Claim 40 (depends on 39)

The NRP1 polypeptide trap of claim 39, wherein said point mutation comprises (a) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to tyrosine 297 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26; (b) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to aspartic acid 320 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26; and/or (c) an amino acid substitution or deletion in domain b1 at an amino acid residue corresponding to glutamic acid 319 of an NRP1 amino acid sequence set forth in FIG. 22 or FIG. 26.

### Claim 41 (depends on 40)

The NRP1 polypeptide trap of claim 40, wherein said mutation point is a Y297A substitution; a D320K substitution and/or a E319K substitution.

### Claim 42 (depends on 32, 33, 34, 35, 36, 37, 38)

The NRP1 polypeptide trap of any one of claims 32 to 38, wherein said trap:
(a) comprises domains a1, a2, b1, b2, and c and of said NRP1 polypeptide;
(b) comprises domains a1, a2, b1 and b2 of said NRP1 polypeptide;
(c) comprises domains a1, a2, and b1 of said NRP1 polypeptide;
(d) comprises domains a1 and a2 said NRP1 polypeptide;
(e) comprises domain b1 of said NRP1 polypeptide, wherein said domain b1 comprises at least one point mutation at an amino acid residue corresponding to (i) tyrosine 297; (ii) aspartic acid 320 and/or (iii) glutamic acid 319, of a NRP1 polypeptide comprising an amino acid sequence as set forth in FIG. 26, wherein said at least one mutation reduces or abrogates binding to VEGF165;
lacks completely or partially domain c of said NRP1 polypeptide;
lacks completely or partially domain b1 of said NRP1 polypeptide;
lacks completely or partially domain b2 of said NRP1 polypeptide;
lacks domains b1 and b2 of said NRP1 polypeptide; or
lacks domains b1, b2 and c of said NRP1 polypeptide.

### Claim 43 (depends on 42)

The NRP1 polypeptide trap of claim 42, wherein (i) said domain a1 comprises or consists essentially of an amino acids sequence corresponding to amino acids 27 to 141 of an NRP1 polypeptide as set forth in FIG. 26; (ii) said domain a2 comprises an amino acid sequence corresponding to amino acids 147 to 265 of an NRP1 polypeptide as set forth in FIG. 26; (iii) said domain b1 comprises an amino acids sequence corresponding to amino acids 275 to 424 of an NRP1 polypeptide as set forth in FIG. 26; (iv) said domain b2 comprises an amino acids sequence corresponding to amino acids 431 to 583 of an NRP1 polypeptide as set forth in FIG. 26; and/or (v) said domain c domain comprises an amino acids sequence corresponding to amino acids 645 to 811 of an NRP1 polypeptide as set forth in FIG. 26.

### Claim 44 (depends on 42)

The NRP1 polypeptide trap of claim 42, wherein (i) said domain a1 comprises or consists essentially of an amino acids sequence corresponding to amino acids 22 to 148 of an NRP1 polypeptide as set forth in FIG. 26; (ii) said domain a2 comprises an amino acid sequence corresponding to amino acids 149 to 275 of an NRP1 polypeptide as set forth in FIG. 26; (iii) said domain b1 comprises an amino acids sequence corresponding to amino acids 276 to 428 of an NRP1 polypeptide as set forth in FIG. 26; (iv) said domain b2 comprises an amino acids sequence corresponding to amino acids 429 to 589 of an NRP1 polypeptide as set forth in FIG. 26; and/or (v) said domain c domain comprises an amino acids sequence corresponding to amino acids 590 to 859 of an NRP1 polypeptide as set forth in FIG. 26.

### Claim 45 (depends on 32)

The NRP1 polypeptide trap of claim 32, wherein said trap consists essentially of a trap as set forth in Table 1 or a functional variant thereof.

### Claim 46 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The NRP1 polypeptide trap of any one of claims 32 to 44, wherein said trap further comprises a protein purification domain.

### Claim 47 (depends on 46)

The NRP1 polypeptide trap of claim 46, wherein said purification domain is a polyhistidine tag.

### Claim 48 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The NRP1 polypeptide trap of any one of claims 32 to 47, wherein said NRP1 trap further comprises a FC domain.

### Claim 49 (depends on 46, 47, 48)

The NRP1 polypeptide trap of any one of claims 46 to 48, wherein said NRP1 trap comprises a protease or peptidase cleavage site enabling said protein purification domain or FC domain to be removed from said NRP1 trap.

### Claim 50 (depends on 49)

The NRP1 polypeptide trap of claim 49, wherein said protease or peptidase cleavage site is a TEV protease cleavage site.

### Claim 51 (depends on 50)

The NRP1 polypeptide trap of claim 50, wherein said TEV protease cleavage site comprises the amino acid sequence GSKENLYFQG.

### Claim 52 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

A nucleic acid encoding the NRP1 polypeptide trap of any one of claims 32-51.

### Claim 53 (depends on 52)

An expression vector comprising the nucleic acid of claim 52.

### Claim 54 (depends on 53)

A host cell comprising the vector of claim 53.

### Claim 55 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A composition comprising the NRP1 polypeptide trap of any one of claims 32 to 51, the nucleic acid of claim 52, the vector of claim 53 or the host cell of claim 54 and a suitable carrier.

### Claim 56 (depends on 55)

The composition of claim 55 for (ii) for preventing or treating inflammation, or (ii) preventing or reducing hyperactivation of innate immune response.

### Claim 57

A compound for preventing or treating inflammation, wherein said compound:
(a) reduces NRP1 expression or activity; and/or
(b) reduces NRP1 ligand expression or activity.

### Claim 58

A compound for preventing or reducing hyperactivation of innate immune response, wherein said compound:
(a) reduces NRP1 expression or activity; and/or
(b) reduces NRP1 ligand expression or activity.

### Claim 59 (depends on 57, 58)

The compound of claim 57 or 58, wherein said compound is:
(i) A anti SEMA3A antibody;
(ii) An anti VEGF165 antibody
(iii) A anti NRP1 antibody;
(iv) A NRP1 trap;
(v) A SEMA3A antisense, shRNA or siRNA;
(vi) A NRP1 antisense, shRNA or siRNA; or
(vii) A VEGF antisense, shRNA or siRNA.

### Claim 60 (depends on 59)

The compound claim 59, wherein said compound is an NRP1 polypeptide trap.

### Claim 61 (depends on 57, 58, 59, 60)

A composition for treating or preventing inflammation comprising a compound as defined in any one of claims 57-60 and a suitable carrier.

### Claim 62 (depends on 57, 58, 59, 60)

A composition for preventing or reducing hyperactivation of innate immune response comprising a compound as defined in of any one of claims 57-60 and a suitable carrier.

### Claim 63 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

Use of the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54, the compound of any one of claims 57-60 or the composition of any one of claims 55, 61 and 62 in the manufacture of a medicament for preventing or treating inflammation.

### Claim 64 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

Use of the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54 the compound of any one of claims 57-60 or the composition of any one of claims 55, 61 and 62 in the manufacture of a medicament for preventing or treating inflammation.

### Claim 65 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

Use of the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54 the compound as defined in any one of claims 57-60 or the composition as defined in any one of claims 55, 61 and 62 for preventing or treating hyperactivation of innate immune response.

### Claim 66 (depends on 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

Use of a the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54 the compound as defined in any one of claims 57-60 or the composition as defined in any one of claims 55, 61 and 62 for preventing or reducing hyperactivation of innate immune response.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein said subject suffers or is likely to suffer from septic shock, arthritis, inflammatory bowel disease (IBD), cutaneous skin inflammation, diabetes, uveitis, diabetic retinopathy, age-related macular degeneration (AMD), retinopathy of prematurity, multiple sclerosis, amyotrophic lateral sclerosis (ALS), age-related cognitive decline/Alzheimer's disease or stroke.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1-31, the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54, a compound as defined in any one of claims 57-60 or a composition as defined in any one of claims 55, 61 and 62 wherein said method, NRP1 polypeptide trap, nucleic acid, vector, host cell, compound, composition or use is for treating or preventing septic shock, arthritis, inflammatory bowel disease (IBD), cutaneous skin inflammation, diabetes, uveitis, diabetic retinopathy, age-related macular degeneration (AMD), retinopathy of prematurity, multiple sclerosis, amyotrophic lateral sclerosis (ALS), age-related cognitive decline/Alzheimer's disease or stroke.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1-31, the NRP1 polypeptide trap of any one of claims 32-51, the nucleic acid of claim 52, the vector of claim 53, the host cell of claim 54, a compound as defined in any one of claims 57-60 or a composition as defined in any one of claims 55, 61 and 62 wherein said method, NRP1 polypeptide trap, nucleic acid, vector, host cell, compound, composition or use is for treating or preventing septic shock or stroke.
